SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D, and D2 receptors

Journal of Neural Transmission

Volumn 103, Issue 1-2, 1996, Pages 17-30

  Markstein, R ^a   Gull, P ^a   Riideberg, C ^a   Urwyler, S ^a   Jaton, A L ^a   Kalkman, H O ^a   Dixon, A K ^a   Hoyer, D ^a  

^a Preclinical Research   (Switzerland)

Author keywords

Circling (rats) rearing (mice); Dopamine d1 receptor; Dopamine d2 receptor, prolactin; Octahydrobenzo g quinoline; SDZ GLC 756

Indexed keywords

1,2,3,4,4A,5,10,10A OCTAHYDRO 6 HYDROXY 1 METHYL 3 [(2 PYRIDYLTHIO)METHYL]BENZO[G]QUINOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ACETYLCHOLINE; ADENYLATE CYCLASE; APOMORPHINE; BROMOCRIPTINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; OCTAHYDROBENZO[G]QUINOLINE; PROLACTIN; QUINOLINE DERIVATIVE; SPIPERONE; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG POTENCY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; RAT; RECEPTOR BINDING;

ACETYLCHOLINE; ADENYLATE CYCLASE; ANIMALS; APOMORPHINE; CATTLE; CEREBRAL CORTEX; DOPAMINE; DOPAMINE AGENTS; DOPAMINE AGONISTS; MALE; MICE; MUSCLE, SMOOTH, VASCULAR; NEOSTRIATUM; NOREPINEPHRINE; OXIDOPAMINE; PROLACTIN; QUINOLINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SEROTONIN; STEREOTYPED BEHAVIOR; SYMPATHOLYTICS;

EID: 0029863250     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01292613     Document Type: Article

References (38)

1. Amt J, Hyttel J (1985) Differential involvement of dopamine D, and D2 receptors in the circling behaviour induced by apomorphine, SKF 38393, pergolide and L Y 171555 in 6-hydroxydopamine-lesioned rats. Psychopharmacology 85: 346-352
2. Braun AR, Chase TN (1986) Obligatory D,/D2 receptor interaction in the generation of dopamine agonist related behaviors. Eur J Pharmacol 131: 301-306
3. 1D binding sites in various species: similar pharmacological profile in dog, monkey, calf, guinea-pig and human brain membranes. Naunyn Schmiedebergs Arch Pharmacol 346: 243-248
4. Carlsson A (1978) Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 135: 164-173
5. Cheng YC, Prusoff WH (1973) Relationship between the inhibition constant Ki and the concentration which caused 50% inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108
6. 3H]205-501, a noncatechol dopaminergic agonist labels selectively and with high affinity for dopamine D2 receptors. J Neural Transm 62: 231-248
7. Christ GJ, Jean-Jaques M (1991) Mutual-effect amplification of contractile response elicited by simultaneous activation of alpha-1 adrenergic and 5-hydroxytryptamine2 receptors in isolated rat aorta. J Pharmacol Exp Ther 256: 553-561
8. 1 receptor antagonists. Eur J Pharmacol 213: 251-258
9. Djamgoz MBA, Wagner HJ (1992) Localization and function of dopamine in the adult vertebrate retina. Neurochem Int 20: 139-191
10. Engel G, Hoyer D, Berthold R, Wagner H (1981) (±)[125 Iodo]cyanopindolol, a new ligand for β-adrenoceptors: Identification and quantification of subclasses of β-adrenoceptors in guinea pig. Naunyn Schmiedebergs Arch Pharmacol 317: 277-285
11. Ford APDW, Williams TJ, Blue DR, Clarke DE (1994) al-adrenoceptor classification: sharpening ocam's razor. Trends Pharmacol Sei 15: 167-170
12. Fouriezos G, Hansson P, Wise RA (1978) Neuroleptic induced attenuation of brain stimulation reward in rats. J Comp Physiol Psychol 92: 661-671
13. Frandsen EK, Krishna G (1976) A simple ultrasensitive method for the assay of cyclic AMP and cyclic GMP in tissues. Life Sei 18: 529-542
14. Furchgott RF (1972) The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. Handbook Exp Pharmacol 33: 283-335
15. Göthert M, Huth H (1980) Alpha-adrenoceptor-mediated modulation of 5-hydroxytryptamine release from rat brain cortex slices. Naunyn Schmiedebergs Arch Pharmacol 313: 21-26
16. Hornykiewicz O (1988) Neurochemical pathology of Parkinson's disease: basic facts and hypothetical possibilities. Mt Sinai J Med 55: 11-20
17. 3H]mesulergine and [3H]ketanserin. Eur J Pharmacol 118: 13-25
18. Hoyer D, Middlemiss DN (1989) Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. Trends Pharmacol Sei 10: 130-132
19. Hyttel J (1984) Functional evidence for selective D-l receptor blockade by SCH 23390. Neuropharmacology 23: 1395-1401
20. Jimerson DC (1987) Role of dopamine mechanisms in the affective disorders. In: Meltzer H (ed) Psychopharmacology. The third generation of progress. Raven Press, New York, pp 505-511
21. Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93-96
22. Markstein R (1986) Pharmacological characterisation of central dopamine receptors using functional criteria. In: Winlow W, Markstein R (eds) The neurobiology of dopaminergic systems. Manchester University Press, Manchester, pp 40-52
23. Markstein R, Enz A, Vigouret JM, Jaton A, Glosse A, Briner U, Gull P (1987) Biochemical, behavioural, and endocrine effects of CK 204-933, a novel 8-β-ergolene. J Neural Transm 69: 179-199
24. McLeod RM, Lehmeyer JE (1974) Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Endocrinology 94: 1077-1084
25. Nordmann R, Flückiger EW, Petcher TJ, Brownell J (1988) Endocrine actions of the potent dopamine D2 agonist CV 205-502 and related octahydrobenz[g]quinolines. Drugs of the Future 13: 951-958
26. Rogawski MA (1987) New directions in neurotransmitter action: dopamine provides some important clues. Trends Neurosci 10: 200-205
27. Ruffolo RR, Waddell JE (1982) Receptor interactions of imidazolines: a-adrenoceptors of rat and rabbit aortae differentiated by relative potencies, affinities and efficacies of imidazoline agonists. Br J Pharmacol 77: 169-176
28. Rüdeberg C, Urwyler S, Schulthess C, Herrling PL (1986) Biochemical and pharmacological effects of fluperlapine on noradrenaline and acetylcholine systems in some rodent, bovine and crustacean preparations. Naunyn Schmiedebergs Arch Pharmacol 332: 357-354
29. Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229-313
30. Sibley DR, Monsma FJ (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sei 13: 61-69
31. Starke K (1980) Presynaptic receptors and the control of noradrenaline release. Trends Pharmacol Sei l: 268-271
32. Starke K, Spath JD, Adelung C (1983) Further functional in vitro comparison of pre- and postsynaptic dopamine receptors in the rabbit caudate nucleus. Naunyn Schmiedebergs Arch Pharmacol 323: 298-306
33. Stoof JC, Thieme RE, Vrijmoe-de Vries MC, Mulder AH (1979) In vitro acetylcholine release from rat caudate nucleus as a new model for testing drugs with dopamine receptor activity. Naunyn Schmiedebergs Arch Pharmacol 309: 119-124
34. Taube HD, Starke K, Borowski E (1977) Presynaptic receptor systems on the noradrenergic neurones of rat brain. Naunyn Schmiedebergs Arch Pharmacol 299: 123-141
35. 1 and D2 dopamine receptors, respectively. J Neurochem 46: 1058-1067
36. Vigouret JM, Buerki HR, Jaton AL, Zueger PE, Loew DM (1978) Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712. Pharmacology 16 [Suppl 1]: 156-173
37. 1D recognition sites: radioligand binding studies in human, pig and calf brain membranes. Naunyn Schmiedebergs Arch Pharmacol 337: 595-601
38. Weiner RI, Ganong WF (1978) Role of brain monoamines and histamine in regulation of anterior pituitary secretion. Physiol Rev 58: 905-976